Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DDA as an immunological adjuvant.

L A Hilgers1, H Snippe

  • 1Solvay S.A., Central Laboratory, Applied Immunology, Brussels.

Research in Immunology
|June 1, 1992
PubMed
Summary

DDA (dimethyldioctadecylammonium) is a potent adjuvant enhancing immune responses, particularly cell-mediated immunity and delayed-type hypersensitivity (DTH). It shows promise for both experimental and veterinary vaccines, with no severe side effects observed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New genetic associations detected in a host response study to hepatitis B vaccine.

Genes and immunity·2010
Same author

Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.

Gene therapy·2007
Same author

[Bicycle spoke injuries in children: accident details and consequences].

Nederlands tijdschrift voor geneeskunde·2002
Same author

Revised interpretation of the immunological results obtained with pneumococcal polysaccharide 17F derived synthetic di-, tri- and tetrasaccharide conjugates in mice and rabbits.

Vaccine·2001
Same author

Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.

Infection and immunity·2001
Same author

Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice.

Infection and immunity·2001

Area of Science:

  • Immunology
  • Vaccinology

Background:

  • Adjuvants are critical for vaccine efficacy, modulating immune responses to antigens.
  • DDA (dimethyldioctadecylammonium) is an adjuvant with known effects on immune responses.

Purpose of the Study:

  • To evaluate the adjuvant properties of DDA against various antigens in different animal models.
  • To explore the potential applications of DDA in vaccine development.

Main Methods:

  • Comparative analysis of DDA's adjuvant activity against humoral and cell-mediated immunity (CMI).
  • Assessment of DTH responses in laboratory and larger animals.
  • Investigation of DDA's synergistic effects with other immunomodulators.

Main Results:

  • DDA demonstrated moderate to strong humoral immune responses and strong CMI, especially DTH responses.
  • DDA exhibited synergistic effects when combined with other immunomodulating compounds.
  • No severe detrimental side effects were observed, indicating a favorable safety profile.

Conclusions:

  • DDA is a potent adjuvant, particularly effective for inducing CMI and DTH responses.
  • Its efficacy and safety profile suggest suitability for experimental and veterinary vaccines.
  • DDA can be a valuable tool for studying T helper type 1 cells and antigen epitopes.

Related Experiment Videos